{"id":"NCT00379288","sponsor":"Organon and Co","briefTitle":"Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)","officialTitle":"A 1-Year Safety Study of Medium and High Doses of Mometasone Furoate/Formoterol Combination Formulation and Medium and High Doses of Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Medium to High Doses of Inhaled Glucocorticosteroids","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-11","completion":"2007-11","firstPosted":"2006-09-21","resultsPosted":"2010-08-12","lastUpdate":"2024-05-20"},"enrollment":404,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"mometasone furoate combination MDI 200/10 mcg BID","otherNames":["SCH 418131"]},{"type":"DRUG","name":"mometasone furoate combination MDI 400/10 mcg BID","otherNames":["SCH 418131"]},{"type":"DRUG","name":"Fluticasone/Salmeterol 250/50 mcg BID","otherNames":["Seretide"]},{"type":"DRUG","name":"Fluticasone/Salmeterol 500/50 mcg BID","otherNames":["Seretide"]}],"arms":[{"label":"MF/F 200/10 mcg BID","type":"EXPERIMENTAL"},{"label":"MF/F 400/10 mcg BID","type":"EXPERIMENTAL"},{"label":"F/SC 250/50 mcg BID","type":"ACTIVE_COMPARATOR"},{"label":"F/SC 500/50 mcg BID","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol combination (F/SC) (250/50 mcg BID and 500/50 mcg BID) in subjects with persistent asthma who require maintenance treatment on inhaled glucocorticosteroids (ICS); evaluator-blind.\n\nIn addition, the extrapulmonary effects on 24-hour plasma cortisol area under curve (AUC), of MF/F MDI 200/10 mcg BID, MF/F MDI 400/10 mcg BID, F/SC MDI 250/50 mcg BID, and F/SC MDI 500/50 mcg BID will be evaluated.","primaryOutcome":{"measure":"The Number of All Randomized Subjects Reporting Adverse Events (AEs).","timeFrame":"1 year","effectByArm":[{"arm":"MF/F 200/10 mcg BID","deltaMin":109,"sd":null},{"arm":"MF/F 400/10 mcg BID","deltaMin":103,"sd":null},{"arm":"F/SC 250/50 mcg BID","deltaMin":56,"sd":null},{"arm":"F/SC 500/50 mcg BID","deltaMin":50,"sd":null}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG000","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG001","p":null},{"comp":"OG002","p":null},{"comp":"OG002","p":null},{"comp":"OG002","p":null},{"comp":"OG002","p":null},{"comp":"OG003","p":null},{"comp":"OG003","p":null},{"comp":"OG003","p":null},{"comp":"OG003","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20874458","36472162","25044280"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":141},"commonTop":["HEADACHE","NASOPHARYNGITIS","BRONCHITIS","INFLUENZA","PHARYNGITIS"]}}